Larimar Therapeutics to Participate in the Guggenheim Genomic Medicines and Rare Disease Days
Lariamar Therapeutics (Nasdaq: LRMR) announced its participation in the Guggenheim Genomic Medicines and Rare Disease Days on April 3-4, 2023.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Lariamar Therapeutics (Nasdaq: LRMR) announced its participation in the Guggenheim Genomic Medicines and Rare Disease Days on April 3-4, 2023. The company will engage in a virtual fireside chat and 1x1 investor meetings, showcasing its focus on developing treatments for complex rare diseases.
The fireside chat is scheduled for April 4, 2023, at 4:35 PM ET, accessible via a live webcast link. Following the event, a replay will be available on Larimar's Events and Presentations page. Larimar Therapeutics is advancing its lead compound, CTI-1601, for Friedreich's ataxia and aims to create further treatments for rare diseases through its innovative platform.
Details
News Market Reaction – LRMR
The recorded move for LRMR in the trading session of this news was -0.45%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BALA CYNWYD, Pa., March 28, 2023 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that company management will participate in a virtual fireside chat and 1x1 investor meetings at the Guggenheim Genomic Medicines and Rare Disease Days, which are taking place from April 3 – 4, 2023.
Details on the fireside chat can be found below.
| Date: | Tuesday, April 4, 2023 |
| Time: | 4:35 PM ET |
| Webcast Link: | https://kvgo.com/gmrdc/larimar-therapeutics-inc-april-2023 |
A live webcast of the fireside chat may be accessed using the link above. Following the conclusion of the fireside chat, a replay will be available on the “Events and Presentations” page of Larimar’s website.
About Larimar Therapeutics
Larimar Therapeutics, Inc. (Nasdaq: LRMR), is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases. Larimar’s lead compound, CTI-1601, is being developed as a potential treatment for Friedreich's ataxia. Larimar also plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds. For more information, please visit: https://larimartx.com.
Investor Contact:
Joyce Allaire
LifeSci Advisors
jallaire@lifesciadvisors.com
(212) 915-2569
Company Contact:
Michael Celano
Chief Financial Officer
mcelano@larimartx.com
(484) 414-2715
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.